Jumped into GH (A US stock) for long
Already prepared for -1, Let's see what is going to happen,
Risked 0.5% on this trade, Will keep updating as whatever happens
LongCompare with Guardant Health, Inc.
−3.50 USD
−416.28 M USD
982.02 M USD
128.82 M
Last report date
Jul 30, 2026
Report period
Q2 2026
EPS
−0.90 USD
Revenue
334.98 M USD
Earnings call summary
Q2 2026 saw 44% revenue growth to $335M, driven by strong oncology, biopharma, and screening performance. Major milestones included FDA approvals, Shield's inclusion in ACS guidelines, and UnitedHealth coverage, expanding access to 70M lives. Full-year guidance was raised on robust demand and operational efficiency.
Details
Sector
Industry
Website
Headquarters
Palo Alto
Founded
2011
IPO date
Oct 9, 2018
ISIN
US40131M1099
CUSIP
40131M109
FIGI
BBG006D97VY9
Identifiers
ISIN US40131M1099
Guardant Health, Inc. is a precision oncology company, which engages in the provision of treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions include treatment selection, recurrence detection, and early detection. The company was founded by Helmy Eltoukhy, AmirAli H. Talasaz, and Michael Joseph Wiley in December 2011 and is headquartered in Palo Alto, CA.
Long
GH - Rounding to previous high=======
Volume
=======
- Increasing
==========
Price Action
==========
- Bullish flag spotted
- Supported above $90
- Moved up from large rounding bottom since 2022 Q3
=================
Technical Indicators
=================
- Ichimoku
>>> price above cloud
>>> Green kumo expanding slightly
>>> Te
Long
TradeUSAsignals RecommendationsGH - Long (3% of your portfolio) - Order filled @ 63.00
An up trend controlled by Time traders with a rebound from the lower boundary of the price channel.
Long
GH 3D: breakout forming inside ascending channelThe price of GH continues consolidating within the top of an ascending channel, confirming bullish structure. The rectangular accumulation has lasted for over three months, with price staying above all major EMAs and MAs - a strong trend confirmation. On the last impulse, volume increased, and now t
Long
GH (Guardant Health) — Breakout Setup with Strong Upside PotentiGuardant Health (GH) is showing signs of completing a long-term accumulation phase and transitioning into a bullish trend. After breaking out of a major descending trendline and holding above key resistance at $38.30, the stock entered a tight consolidation range — a classic base formation before a
Long
Guardant Surge: Targeting a Clean Breakout!”“Guardant Surge: Targeting a Clean Breakout!”
📝 Trade Breakdown:
🧬 Setup:
GH is showing a strong breakout retest pattern after breaking above consolidation near $48. The price is holding above support, forming a higher low with momentum.
📍 Entry: ~$49.53 (post-breakout retest)
🎯 Target: $52.40 (re
Long
In the Genes for GH’s Path.Guardant Health is building strong bullish momentum, with a gap forming around the $21.50 level. A breakout above the $26.37 resistance would signal further upward movement, targeting the $37.05 weekly resistance. With an appealing 3.6 risk-to-reward ratio, this trade offers an attractive short-term
Long
Guardant Health (GH) - Double/Triple bottom incoming The chart shows a strong bearish trend that started in February 2021 and is not finished yet. It coincides with an ABC wave pattern of Elliott's Wave Theory. Despite this, it is likely that the price is near the end of this downtrend with the possibility of a new upcoming impulse. This is due to the
Long
biotech and GH looking to trend upwardGH and a few others looking to continue ascending channels/triangles into possible upward breakouts, 40+ impending
Long
GH dead cat bounceGuardian Health has had nothing more than a dead cat bounce along with the overall market today, the long term chart is in a nasty downtrend and we're in a bear market, rallies are to be sold, not bought
Short
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Maturity dateNov 15, 2027
Coupon0% (Zero)
Maturity dateFeb 15, 2031
Coupon1.25% (Fixed)
See all GH bonds
Frequently asked questions
The current price of GH is 168.48 USD — it has increased by 6.92% in the past 24 hours. Watch Guardant Health, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Guardant Health, Inc. stocks are traded under the ticker GH.
GH stock has risen by 3.68% compared to the previous week, the month change is a 5.77% rise, over the last year Guardant Health, Inc. has showed a 223.81% increase.
We've gathered analysts' opinions on Guardant Health, Inc. future price: according to them, GH price has a max estimate of 225.00 USD and a min estimate of 180.00 USD. Watch GH chart and read a more detailed Guardant Health, Inc. stock forecast: see what analysts think of Guardant Health, Inc. and suggest that you do with its stocks.
GH stock is 7.26% volatile and has beta coefficient of 1.34. Track Guardant Health, Inc. stock price on the chart and check out the list of the most volatile stocks — is Guardant Health, Inc. there?
Today Guardant Health, Inc. has the market capitalization of 22.61 B, it has decreased by −4.73% over the last week.
Yes, you can track Guardant Health, Inc. financials in yearly and quarterly reports right on TradingView.
Guardant Health, Inc. is going to release the next earnings report on Oct 29, 2026. Keep track of upcoming events with our Earnings Calendar.
GH earnings for the last quarter are −0.90 USD per share, whereas the estimation was −0.76 USD resulting in a −18.14% surprise. The estimated earnings for the next quarter are −0.75 USD per share. See more details about Guardant Health, Inc. earnings.
Guardant Health, Inc. revenue for the last quarter amounts to 334.98 M USD, despite the estimated figure of 314.23 M USD. In the next quarter, revenue is expected to reach 349.15 M USD.
GH net income for the last quarter is −120.14 M USD, while the quarter before that showed −112.08 M USD of net income which accounts for 0.00% change. Track more Guardant Health, Inc. financial stats to get the full picture.
No, GH doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Aug 8, 2026, the company has 2.51 K employees. See our rating of the largest employees — is Guardant Health, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Guardant Health, Inc. EBITDA is −431.28 M USD, and current EBITDA margin is −40.38%. See more stats in Guardant Health, Inc. financial statements.
Like other stocks, GH shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Guardant Health, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Guardant Health, Inc. technincal analysis shows the strong buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Guardant Health, Inc. stock shows the buy signal. See more of Guardant Health, Inc. technicals for a more comprehensive analysis.